Trial Profile
Confirmatory study of patients with progressive autosomal dominant polycystic kidney disease (ADPKD) to establish the determinants of disease progression and response to tolvaptan treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- 30 Sep 2021 According to UMIN, the date for data entry closure is 31 March 2019, and date for conclusion of data analysis is 31 March 2021.
- 30 Sep 2021 Status changed from recruiting to completed.
- 30 Sep 2014 New trial record